Genmab A (GMAB) Invested Capital (2019 - 2025)

Genmab A (GMAB) posted Invested Capital of $5.3 billion for Q4 2025, up 37571.43% on a QoQ basis from $14.0 million in Q1 2025.

Genmab A (GMAB) Invested Capital (2019 - 2025) Analysis & Trends

Genmab A's Invested Capital history runs 3 years deep, the most recent figure standing at $5.3 billion for Q4 2025.

Quarterly Invested Capital changed N/A year-over-year to $5.3 billion in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $5.3 billion (up 37571.43% YoY) and the FY2025 annual result came in at $5.3 billion, changed N/A from the prior year.
Invested Capital was $5.3 billion for Q4 2025 at Genmab A, up from $14.0 million in the prior quarter.
Across five years, Invested Capital topped out at $5.3 billion in Q4 2025 and bottomed at $14.0 million in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Invested Cap. (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	110.96 Mn
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	116.14 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Genmab A	1.89 Bn	366.92 Mn	831.00 Mn	-

Download Data